In the AUGUSTUS trial, 4614 patients with AF and either ACS or undergoing elective PCI were randomized in a 2 × 2 factorial design to aspirin or placebo and to apixaban or VKA, in addition to P2Y12 inhibitor [22]. The gene discussed is P2RY12; the disease is atrial fibrillation.